← Back to Search

Local Anesthetic

Liquid Lidocaine for Stroke

Phase 2
Recruiting
Led By Adam H de Havenon, MD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

Study Summary

This trial will test whether SPG block can relieve post-stroke headache.

Eligible Conditions
  • Stroke
  • Ischemic Stroke
  • Headache

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Number of Migraine Headaches During Treatment Phase
Secondary outcome measures
Adverse effect
Numeric Pain Rating Scale

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Liquid LidocaineExperimental Treatment1 Intervention
The investigational treatment is 1.5 mL of aqueous 2% lidocaine.
Group II: Sham PlaceboPlacebo Group1 Intervention
The placebo arm is 1.5mL of aqueous of saline.

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,095 Previous Clinical Trials
1,775,565 Total Patients Enrolled
19 Trials studying Stroke
3,437 Patients Enrolled for Stroke
Adam H de Havenon, MDPrincipal InvestigatorUniversity of Utah

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a danger associated with Liquid Lidocaine?

"This substance has received a score of 2 for safety. While there have been Phase 2 trials conducted which suggest it is safe, there is no data to support its efficacy."

Answered by AI
Recent research and studies
The Journal of Headache and PainJournal
Sphenopalatine Ganglion: Block, Radiofrequency Ablation and Neurostimulation - a Systematic Review
Ho, Kwo Wei David, Rene Przkora, and Sanjeev Kumar. 2017. “Sphenopalatine Ganglion: Block, Radiofrequency Ablation and Neurostimulation - a Systematic Review”. The Journal of Headache and Pain. Springer Science and Business Media LLC. doi:10.1186/s10194-017-0826-y.
Headache: The Journal of Head and Face PainJournal
A Double‐blind, Placebo‐controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With<scp>t</scp>x360<sup>®</sup>as Acute Treatment for Chronic Migraine
Cady, Roger, Joel Saper, Kent Dexter, and Heather R. Manley. 2014. “A Double‐blind, Placebo‐controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade Withtx360®as Acute Treatment for Chronic Migraine”. Headache: The Journal of Head and Face Pain. Wiley. doi:10.1111/head.12458.
Headache: The Journal of Head and Face PainJournal
A Narrative Review of Persistent Post-stroke Headache - A New Entry in the International Classification of Headache Disorders, 3rd Edition
Lai, Joshua, Rebecca A. Harrison, Alyson Plecash, and Thalia S. Field. 2018. “A Narrative Review of Persistent Post-stroke Headache - A New Entry in the International Classification of Headache Disorders, 3rd Edition”. Headache: The Journal of Head and Face Pain. Wiley. doi:10.1111/head.13382.
Headache: The Journal of Head and Face PainJournal
Hemicrania Continua May Respond to Repetitive Sphenopalatine Ganglion Block: A Case Report
Michelle Androulakis, X., Kaitlin A. Krebs, and Avi Ashkenazi. 2016. “Hemicrania Continua May Respond to Repetitive Sphenopalatine Ganglion Block: A Case Report”. Headache: The Journal of Head and Face Pain. Wiley. doi:10.1111/head.12783.
All > Headache
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top